SCHEMBL30714596

SCHEMBL30714596

Cn1nc2ccc(OCc3ccccc3)cc2c1C(=O)NCC1CCC(=O)N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 2/20 0.43
CD274 Q9NZQ7 2/20 0.41
MMP13 P45452 1/20 0.41
GSK3B P49841 1/20 0.40
NMT1 P30419 2/20 0.40
IP6K1 Q92551 1/20 0.40
CREBBP Q92793 1/20 0.39
NTRK1 P04629 2/20 0.38
KIT P10721 1/20 0.38
FLT3 P36888 1/20 0.38
MCHR1 Q99705 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HDAC3 O15379 1/20 0.37
APP P05067 1/20 0.37
ACHE P22303 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714723 0.87 CD274 (0.38) CD274NTRK1
SCHEMBL30714588 0.85 CD274 (0.36) CD274NTRK1MCHR1
SCHEMBL30714635 0.84 CD274 (0.37) CD274NTRK1
SCHEMBL24470760 0.78 CASP3 (0.59) CD274MEN1KMT2A
SCHEMBL30714676 0.78 APOL1 (0.49) HTR3AMMP13NMT1IP6K1MCHR1
SCHEMBL30656317 0.77 CD274 (0.44) CD274GSK3BCREBBPMEN1KMT2A
SCHEMBL26696088 0.76 SRD5A2 (0.50) NMT1IP6K1MEN1KMT2A
SCHEMBL30714592 0.76 EGLN2 (0.45) HTR3AMMP13NMT1IP6K1MEN1
SCHEMBL30714713 0.76 HTR3A (0.51) HTR3AMCHR1
SCHEMBL30714748 0.74 HTR3A (0.43) HTR3AMMP13NMT1IP6K1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 HTR3A 62/4885CD274 3915/4885MMP13 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.